Please see the resources below to learn more about the issues surrounding the use of biosimilars. 


June 10, 2014

National Alliance for Hispanic Health Letter to FDA

On June 10, the National Alliance for Hispanic Health and twenty-two undersigned groups, representing millions of U.S. patients and professional caregivers involved in minority health, sent a letter to FDA urging for distinguishable names for biosimilars. Read More ›

June 3, 2014

NORD Letter to FDA on Distinguishable Naming

On June 3, the National Organization for Rare Disorders (NORD) sent a letter to FDA Commissioner Hamburg advocating for distinguishable naming for biosimilars.  Read More ›

May 20, 2014

Society for Women’s Health Research (SWHR) and patient advocates Letter to FDA

On May 20, SWHR and 45 patient advocacy groups sent a letter urging FDA to consider gender-based Disparities in medical research and treatment when establishing an approach to biosimilar naming. Read More ›